Cite
Ruxolitinib-loaded cytokine nanosponge alleviated the cytokine storm and dampened macrophage overactivation for the treatment of hemophagocytic lymphohistiocytosis.
MLA
Wang, Honglan, et al. “Ruxolitinib-Loaded Cytokine Nanosponge Alleviated the Cytokine Storm and Dampened Macrophage Overactivation for the Treatment of Hemophagocytic Lymphohistiocytosis.” International Journal of Pharmaceutics, vol. 657, May 2024, p. N.PAG. EBSCOhost, https://doi.org/10.1016/j.ijpharm.2024.124127.
APA
Wang, H., Wang, Y., Liu, H., Li, X., Sun, C., Pang, Z., Zhang, B., & Hu, Y. (2024). Ruxolitinib-loaded cytokine nanosponge alleviated the cytokine storm and dampened macrophage overactivation for the treatment of hemophagocytic lymphohistiocytosis. International Journal of Pharmaceutics, 657, N.PAG. https://doi.org/10.1016/j.ijpharm.2024.124127
Chicago
Wang, Honglan, Yiwei Wang, Huiwen Liu, Xuejing Li, Chunyan Sun, Zhiqing Pang, Bo Zhang, and Yu Hu. 2024. “Ruxolitinib-Loaded Cytokine Nanosponge Alleviated the Cytokine Storm and Dampened Macrophage Overactivation for the Treatment of Hemophagocytic Lymphohistiocytosis.” International Journal of Pharmaceutics 657 (May): N.PAG. doi:10.1016/j.ijpharm.2024.124127.